
94% of researchers rate our articles as excellent or good
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.
Find out more
BRIEF RESEARCH REPORT article
Front. Public Health
Sec. Occupational Health and Safety
Volume 13 - 2025 | doi: 10.3389/fpubh.2025.1523207
This article is part of the Research Topic Patient and Medical Staff Safety and Healthy Work Environment in the 21st Century View all 30 articles
The final, formatted version of the article will be published soon.
You have multiple emails registered with Frontiers:
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
This report presents two cases of chemical pneumonitis caused by the exposure of sodium ibandronate powder, a bisphosphonate used for treating osteoporosis. They are both pharmaceutical workers, and they inhaled the powder after an accidental spill in the lab. They developed similar symptoms, but different imaging features, only one showed fibrotic changes. After the blood test and Bronchoscopy examination, they both diagnosed as chemical pneumonitis. Their symptoms improved after treatment with glucocorticoids. Their lung lesions resolved completely after continued treatment. The findings suggest that the importance of appropriate safety measures in environments where pharmaceutical powders may be handled, such as in the pharmaceutical industry. Chemical pneumonitis from inhaled sodium ibandronate can have varying CT appearances and may benefit from glucocorticoids therapy.
Keywords: Chemical pneumonitis, Sodium ibandronate, Exposure, Steroid treatment, case report
Received: 05 Nov 2024; Accepted: 17 Feb 2025.
Copyright: © 2025 Pan, Ma and Qian. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence:
Ting Pan, Zhejiang University, Hangzhou, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Research integrity at Frontiers
Learn more about the work of our research integrity team to safeguard the quality of each article we publish.